DGX vs. LH, DVA, CHE, RCM, CRVL, AMED, AMN, MD, CCRN, and NTRA
Should you be buying Quest Diagnostics stock or one of its competitors? The main competitors of Quest Diagnostics include Laboratory Co. of America (LH), DaVita (DVA), Chemed (CHE), R1 RCM (RCM), CorVel (CRVL), Amedisys (AMED), AMN Healthcare Services (AMN), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Natera (NTRA).
Laboratory Co. of America (NYSE:LH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
95.9% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 0.9% of Laboratory Co. of America shares are owned by company insiders. Comparatively, 0.8% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Quest Diagnostics has a net margin of 9.11% compared to Quest Diagnostics' net margin of 3.52%. Laboratory Co. of America's return on equity of 15.52% beat Quest Diagnostics' return on equity.
Laboratory Co. of America pays an annual dividend of $2.88 per share and has a dividend yield of 1.5%. Quest Diagnostics pays an annual dividend of $2.84 per share and has a dividend yield of 2.0%. Laboratory Co. of America pays out 57.9% of its earnings in the form of a dividend. Quest Diagnostics pays out 38.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Laboratory Co. of America has raised its dividend for 1 consecutive years and Quest Diagnostics has raised its dividend for 1 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and lower payout ratio.
Laboratory Co. of America currently has a consensus price target of $241.86, indicating a potential upside of 23.02%. Quest Diagnostics has a consensus price target of $146.67, indicating a potential upside of 3.04%. Given Quest Diagnostics' stronger consensus rating and higher probable upside, research analysts clearly believe Laboratory Co. of America is more favorable than Quest Diagnostics.
Quest Diagnostics has lower revenue, but higher earnings than Laboratory Co. of America. Quest Diagnostics is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
In the previous week, Laboratory Co. of America had 6 more articles in the media than Quest Diagnostics. MarketBeat recorded 11 mentions for Laboratory Co. of America and 5 mentions for Quest Diagnostics. Laboratory Co. of America's average media sentiment score of 1.16 beat Quest Diagnostics' score of 0.88 indicating that Quest Diagnostics is being referred to more favorably in the news media.
Laboratory Co. of America received 80 more outperform votes than Quest Diagnostics when rated by MarketBeat users. Likewise, 64.11% of users gave Laboratory Co. of America an outperform vote while only 49.43% of users gave Quest Diagnostics an outperform vote.
Laboratory Co. of America has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
Summary
Laboratory Co. of America beats Quest Diagnostics on 11 of the 20 factors compared between the two stocks.
Get Quest Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quest Diagnostics Competitors List
Related Companies and Tools
